|
|
Article: Researchers' work from Johns Hopkins University focuses on granulomatosis therapy.
- Article from:
- Blood Weekly
- Article date:
- November 6, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New investigation results, 'Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations,' are detailed in a study published in Journal of Rheumatology. According to recent research published in the Journal of Rheumatology, "Patients with limited Wegener's granulomatosis (WG) may experience a relapsing and remitting course. How such patients should be treated, particularly when they are refractory to standard of care therapies, is not clear."
"Rituximab is a monoclonal anti-CD20 antibody that has been used successfully to treat multiple forms of autoimmune and rheumatic diseases, but its role in the treatment of limited ...
Related newspaper, magazine, and journal articles:
|
|
Article: Johns Hopkins and Lucent Technologies to Develop ...
PR Newswire;
December 14, 1999 ;
700+ words
... ... BALTIMORE, Dec. 14 /PRNewswire/ -- Johns Hopkins Medicine and Lucent Technologies ... Under the agreement, Lucent and Johns Hopkins International L.L.C., (JHI ... advance the international objectives of Johns Hopkins Medicine -- will jointly design a ...
|
|